Healthcare Global Enterprises Ltd

- Indore and Nagpur acquisitions were partly funded by debt and partly by internal accruals, leading to a slight increase in net debt this quarter. - Maintenance capex is expected to remain around INR 70-75 crores annually, aside from growth plans. - No explicit mention of any new fundraising through debt or equity in the near term in the transcript. - CFO noted that there was a slight increase in net debt due to acquisitions but no specific plans for new debt raising were shared. - Focus appears to be on internal accruals and controlled capex for expansion. - No indications of equity fundraising or plans to raise fresh capital through issuance mentioned. - Management is focused on growth and operational efficiencies without stating new fundraising. Overall, the company has not announced any current or future fundraising through debt or equity beyond what has already been done for recent acquisitions.

- North Bangalore: Planned state-of-the-art 100-bedded premium facility with expected capital outlay of ~INR90 crores; operational timeline of 15-18 months. - Ahmedabad: Expansion from a 100-bedded to 200-bedded premium hospital; capital investment includes about INR106 crores for this project; already spent INR48 crores. - Whitefield (Bangalore): Stand-alone 25-bedded comprehensive cancer center focusing on women's cancers; planned capex ~INR25 crores. - Indore: Acquired hospital with plans for future capacity expansion by 100 beds (Phase II), with ongoing integration and value creation projects. - Maintenance Capex: Expected around INR70-75 crores annually, excluding growth-related capex. - Total bed additions: Approximately 350 beds to be added over next 3 years including Ahmedabad and Whitefield expansions. These investments align with HCG's growth and market expansion strategy focused on premium cancer care facilities.

- HCG aims to grow faster than the market, which is expanding at about 10-11% annually. - Mature centers showed adjusted revenue growth of approximately 12% after accounting for operational adjustments. - Emerging centers are expected to drive higher incremental growth, with some centers like Kolkata and Mumbai showing strong revenue growth (57% and 17% respectively). - Capacity expansions planned (e.g., new 100-bed facility in North Bangalore and additional beds in Indore) will support volume growth without current capacity constraints. - Increased ARPOB (Average Revenue per Occupied Bed) is a key lever for growth, with ARPOB already rising across many centers. - Investments in clinical talent and technology (e.g., radiation machines) are expected to improve volume and revenue mix. - HCG expects continued volume and revenue growth through new center ramp-ups, better service mix, and geographic expansion.

- HCG aims to grow faster than the market, which is growing at about 10-11%, leveraging a strong growth pipeline and existing hospitals. - EBITDA margins are targeted around 20%, but may fall short in the next 1-2 quarters due to new centers (Indore, Whitefield) initially pulling margins down. - Mature centers have shown steady growth with EBITDA margins around 24%, emerging centers improving with steady EBITDA growth. - ARPOB (average revenue per occupied bed) is increasing, driven by emerging centers in bigger cities with more affluent populations, supporting profitability. - Investments in new technologies (e.g., radiation machines) and better service mix are expected to improve contribution and gross margins going forward. - Expansion plans include gradual capacity additions in mature centers, maintaining occupancy and revenue growth potential without capacity constraints in next 3-4 years. - Capex maintained around INR 70-75 crores for maintenance; acquisition-driven debt is manageable with improving cash flows projected.

The transcript provided from Healthcare Global Enterprises Limited does not mention any details about the current or expected order book or pending orders. The discussion largely focuses on operational performance, expansion plans, EBITDA margins, capacity additions, payer mix, ARPOB (average revenue per occupied bed), and future growth strategies. Key highlights related to operations and plans: - Expansion with new facilities like the North Bangalore 100-bed hospital (to be operational in 15-18 months). - Capacity additions in mature centers (e.g., 60 additional beds including Baroda). - Steady improvement in EBITDA margin, targeting ~20%. - Integration and upgrades underway at Indore hospital. - Focus on centers of excellence achieving EBITDA margins around 30%. - Growth plans aligned with expanding capacity and improving revenue mix. No specific references to orderbook or pending orders were disclosed in this call.